New Haven Pharmaceuticals announced the launch of Durlaza (aspirin extended-release) capsules for the secondary prevention of stroke and acute cardiac events, including myocardial infarction in high-risk cardiovascular patients. It was approved by the Food and Drug Administration (FDA) in September 2015.

Durlaza uses extended-release, microcapsule technology to prolong aspirin release. The 24-hour delivery helps maximize its benefit by providing sustained platelet inhibition with the potential for improved patient adherence and compliance.

RELATED: New Data Support Sustained Antiplatelet Effects With Durlaza

Durlaza works by inhibiting prostaglandin synthesis which results in inhibition of platelet aggregation for their lifespan of about 7 to 10 days. The acetyl group of aspirin binds with a serine residue of COX-1 resulting in irreversible inactivation of the enzyme. Inhibition of COX-1 prevents conversion of arachidonic acid to thromboxane A2, a potent agonist of platelet aggregation.

Durlaza is available as 162.5mg strength capsules in 30- and 90-count bottles.

For more information call (877) 824-2483 or visit